rilonacept (Arcalyst)
rilonacept is an FDA-licensed reference biologic from Kiniksa Pharmaceuticals (UK), Ltd.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2008
Reference approved
Reference product
Arcalyst rilonacept
Kiniksa Pharmaceuticals (UK), Ltd.
- Approved
- Feb 27, 2008
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for rilonacept, in chronological order.
Reference approval
Approval date of the reference rilonacept product.
18 yr 6 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
in 1 yr 10 mo
Frequently asked questions
Are there biosimilars approved for rilonacept (Arcalyst)?
No 351(k) biosimilars or interchangeable biosimilars referencing rilonacept are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.